Cell
. 2022 Jan 4;S0092-8674(21)01578-6.
doi: 10.1016/j.cell.2021.12.046. Online ahead of print.
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Wanwisa Dejnirattisai 1 , Jiandong Huo 2 , Daming Zhou 3 , Jiří Zahradník 4 , Piyada Supasa 1 , Chang Liu 5 , Helen M E Duyvesteyn 2 , Helen M Ginn 6 , Alexander J Mentzer 7 , Aekkachai Tuekprakhon 1 , Rungtiwa Nutalai 1 , Beibei Wang 1 , Aiste Dijokaite 1 , Suman Khan 4 , Ori Avinoam 4 , Mohammad Bahar 2 , Donal Skelly 8 , Sandra Adele 9 , Sile Ann Johnson 9 , Ali Amini 10 , Thomas G Ritter 11 , Chris Mason 11 , Christina Dold 12 , Daniel Pan 13 , Sara Assadi 14 , Adam Bellass 14 , Nicola Omo-Dare 14 , David Koeckerling 15 , Amy Flaxman 16 , Daniel Jenkin 16 , Parvinder K Aley 17 , Merryn Voysey 17 , Sue Ann Costa Clemens 18 , Felipe Gomes Naveca 19 , Valdinete Nascimento 19 , Fernanda Nascimento 19 , Cristiano Fernandes da Costa 20 , Paola Cristina Resende 21 , Alex Pauvolid-Correa 22 , Marilda M Siqueira 21 , Vicky Baillie 23 , Natali Serafin 23 , Gaurav Kwatra 23 , Kelly Da Silva 23 , Shabir A Madhi 23 , Marta C Nunes 23 , Tariq Malik 24 , Peter J M Openshaw 25 , J Kenneth Baillie 26 , Malcolm G Semple 27 , Alain R Townsend 28 , Kuan-Ying A Huang 29 , Tiong Kit Tan 30 , Miles W Carroll 31 , Paul Klenerman 32 , Eleanor Barnes 32 , Susanna J Dunachie 33 , Bede Constantinides 34 , Hermione Webster 34 , Derrick Crook 34 , Andrew J Pollard 12 , Teresa Lambe 35 , OPTIC Consortium; ISARIC4C Consortium; Neil G Paterson 6 , Mark A Williams 6 , David R Hall 6 , Elizabeth E Fry 2 , Juthathip Mongkolsapaya 36 , Jingshan Ren 37 , Gideon Schreiber 38 , David I Stuart 39 , Gavin R Screaton 40
Collaborators, Affiliations
- PMID: 35081335
- DOI: 10.1016/j.cell.2021.12.046
Abstract
On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.
Keywords: Omicron; RBD; SARS-CoV-2; Spike; immune evasion; receptor interaction; vaccines; variants.